News
Key results with the next-gen CEA ISAC are below: Bolt’s PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback